Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumers Union supplement survey

This article was originally published in The Tan Sheet

Executive Summary

Nine in 10 consumers want dietary supplements to be proven safe and effective before being marketed, according to a new survey announced June 7 by Consumer Reports publisher Consumers Union. The random sample online survey of 1,221 adults also found that 96% of patients feel supplement makers should be required to report health problems caused by their products and label them with risk information. Eight in 10 respondents agreed that "poor regulation posed a risk to their and their family's health" while only 19% felt supplements are "sufficiently regulated." CR recently published an article naming 12 supplements the "dirty dozen" that consumers should avoid (1"The Tan Sheet" April 5, 2004, p. 13)...

You may also be interested in...



Consumer Reports Article Highlights “Dangerous” Supplements

The dietary supplement industry faces more negative publicity after a Consumer Reports article dubbed twelve supplements the "dirty dozen" that consumers should avoid

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel